empagliflozin + sitagliptin + metformin

Empagliflozin + sitagliptin + metformin is a triple oral combination therapy used for the management of type 2 diabetes mellitus. This regimen combines three antihyperglycemic agents with complementary mechanisms of action: - **Empagliflozin** is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose by increasing urinary glucose excretion through inhibition of glucose reabsorption in the kidneys. - **Sitagliptin** is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, thereby enhancing insulin secretion and suppressing glucagon release in response to meals. - **Metformin** is a biguanide that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity. This combination targets multiple pathophysiological defects in type 2 diabetes and may be considered when dual therapy does not achieve glycemic targets. The triple combination has been studied for efficacy and safety as an add-on regimen[8]. There are currently no widely approved fixed-dose branded products containing all three agents together; however, each component exists as individual or dual-combination products.

Brand names

EmpaSugEmpaSug-SM

Other names

Empagliflozin/Metformin/SitagliptinMetformin/Empagliflozin/SitagliptinSitagliptin/Empagliflozin/Metformin